Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) announced
today that its President and Chief Executive Officer Spiro Rombotis will
present at the 7th Annual BIO Investor Forum
taking place in San Francisco October 29 – 31,
2008. Cyclacel’s presentation will take place
on Wednesday, October 29 at 1:45 p.m. PT.
Cyclacel’s presentation will be webcast live
and archived for 90 days on the Corporate Presentations page of the
Cyclacel website at www.cyclacel.com.
About Cyclacel Pharmaceuticals, Inc.
Cyclacel is a biopharmaceutical company dedicated to the discovery,
development and commercialization of novel, mechanism-targeted drugs to
treat human cancers and other serious disorders. Three orally-available
Cyclacel drugs are in clinical development. Sapacitabine (CYC682), a
cell cycle modulating nucleoside analog, is in Phase 2 studies for the
treatment of acute myeloid leukemia in the elderly, myelodysplastic
syndromes and cutaneous T-cell lymphoma. Seliciclib (CYC202 or
R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2
for the treatment of lung cancer and nasopharyngeal cancer and in Phase
1 in combination with Tarceva®.
CYC116, an Aurora kinase and VEGFR2 inhibitor, is in Phase 1 in patients
with solid tumors. Several additional programs are at an earlier stage.
Cyclacel’s ALIGN Pharmaceuticals subsidiary
markets directly in the U.S. Xclair™ Cream for
radiation dermatitis, Numoisyn™ Liquid and
Numoisyn™ Lozenges for xerostomia. Cyclacel’s
strategy is to build a diversified biopharmaceutical business focused in
hematology, oncology and other therapeutic areas based on a portfolio of
commercial products and a development pipeline of novel drug candidates.
Please visit www.cyclacel.com
for additional information. Note: The Cyclacel logo and Cyclacel®
are trademarks of Cyclacel Pharmaceuticals, Inc.; Numoisyn™
and Xclair™ are trademarks of Sinclair Pharma
plc; Tarceva® is a
trademark of OSI Pharmaceuticals, Inc.
Risk Factors
This news release contains certain forward-looking statements that
involve risks and uncertainties that could cause actual results to be
materially different from historical results or from any future results
expressed or implied by such forward-looking statements. Such
forward-looking statements include statements regarding, among other
things, the efficacy, safety, and intended utilization of Cyclacel's
product candidates, the conduct and results of future clinical trials,
plans regarding regulatory filings, future research and clinical trials
and plans regarding partnering activities. Factors that may cause actual
results to differ materially include the risk that product candidates
that appeared promising in early research and clinical trials do not
demonstrate safety and/or efficacy in larger-scale or later clinical
trials, the risk that Cyclacel will not obtain approval to market its
products, the risks associated with reliance on outside financing to
meet capital requirements, and the risks associated with reliance on
collaborative partners for further clinical trials, development and
commercialization of product candidates. You are urged to consider
statements that include the words "may," "will," "would," "could,"
"should," "believes," "estimates," "projects," "potential," "expects,"
"plans," "anticipates," "intends," "continues," "forecast," "designed,"
"goal," or the negative of those words or other comparable words to be
uncertain and forward-looking. These factors and others are more fully
discussed under "Risk Factors" in the Annual Report on Form 10-K for the
year ended December 31, 2007, as supplemented by the interim quarterly
reports, filed with the SEC.
Cyclacel Pharmaceuticals, Inc.
Corey Sohmer, 908-517-7330
or
WeissComm
Partners
Aline Schimmel, 312-646-6295
or
College Hill,
Life Sciences
Sue Charles or Justine Lamond, +44 (20) 7866 7857
